Similar Search Results

Reference Pricing as a Deterrent to Entry : Evidence from the European Pharmaceutical Market

Maini, Luca; Pammolli, Fabio - 2020

External reference pricing (ERP), the practice of benchmarking domestic drug prices to foreign prices, generates an incentive for firms to withhold products from low-income countries. Using a novel moment inequality approach, we estimate a structural model to measure the extent to which ERP...

Persistent link: https://www.econbiz.de/10014093683

Pharmaceutical regulation, mandatory substitution, and generic competition

Birg, Laura - 2015

This paper studies the effect of two regulatory instruments - a price cap and a reference price system - a mandatory substitution rule, and the combination of both on generic competition in a Salop-type model with an off-patent brand-name drug and n differentiated generic versions. The price cap...

Persistent link: https://www.econbiz.de/10010510801

Implementing personalized medicine with asymmetric information on prevalence rates

Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo A. - In: Health economics review 6 (2016) 35, pp. 1-8

Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...

Persistent link: https://www.econbiz.de/10011586604

Product line extensions under the threat of entry: evidence from the UK pharmaceuticals market

Bokhari, Farasat A. S.; Yan, Weijie - 2020

pharmaceuticals to examine how incumbents respond to change in the threat of entry. In line with the entry deterrence motive …

Persistent link: https://www.econbiz.de/10012285099

Biologic Drugs, Biosimilars, and Barriers to Entry

Shepherd, Joanna - 2014

Biologic drugs represent an important category of drugs that improve health outcomes in this country. Yet, these cutting-edge drugs are often prohibitively costly, preventing access for many Americans. Recognizing the need for more affordable, generic substitutes for biologic drugs — or...

Persistent link: https://www.econbiz.de/10014148056

Does reference pricing drive out generic competition in pharmaceutical markets? : evidence from a policy reform

Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune - 2022

Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...

Persistent link: https://www.econbiz.de/10013285854

Pioneering Advantage in Generic Drug Competition

Yu, Yu - 2014

Pharmaceutical markets experience the entry of numerous generic firms upon expiration of the brand firm's patent. In this paper, we take a close look at competition among the generic entrants during the first three years after patent expiration and examine whether there is a first mover...

Persistent link: https://www.econbiz.de/10012709667

Relationship between the Number of Firms and Generic Drug Price Competition

Jambulingam, Thani - 2011

The theoretical relationship between market structure (number of firms) and conduct (pricing behavior) of the generic drug industry was investigated. The effects of qualitative variables such as therapeutic category, duration of use, popularity, and market entry aggressiveness on the...

Persistent link: https://www.econbiz.de/10013128541

Switching costs, brand premia and behavioral pricing in the pharmaceutical market

Janssen, Aljoscha - 2020

mimics a reduction of switching costs and increases prices. While the effect of switching costs on prices in theory is …

Persistent link: https://www.econbiz.de/10012161505

Price dynamics of Swedish pharmaceuticals

Janssen, Aljoscha - 2020

This paper investigates price patterns of off-patent pharmaceuticals in Sweden. I show that price dynamics are … competition in which the demand for pharmaceuticals incorporates the known biases of consumers: habit persistence and brand … preferences. Using the regulated market of Swedish pharmaceuticals, I show that price may help in identifying possible tacit …

Persistent link: https://www.econbiz.de/10012181078